New combo aims to shrink lung tumors before surgery in targeted trial
NCT ID NCT07256509
First seen Jan 08, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This study tests whether adding the experimental drug SYS6010 to the standard targeted therapy osimertinib works better than osimertinib alone before surgery for people with a certain type of lung cancer (EGFR-mutant, non-squamous, stage II-IIIB). About 120 adults aged 18-75 who can have their tumor surgically removed will receive the drug combination or osimertinib alone for a few weeks before surgery. The main goal is to see if the combination leads to fewer cancer cells remaining in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.